The earnings transcript for Amgen Inc. reveals a strong performance in Q4 and full-year 2011, with record sales and a solid outlook for 2012. The company's pipeline is robust, with several promising products, including XGEVA and Prolia, which are expected to drive growth. The acquisition of Micromet is also seen as a strategic move to enhance Amgen's pipeline and R&D capabilities. Management's tone is optimistic, with a focus on delivering growth and expanding the company's global presence. The guidance for 2012 is positive, with expected revenue growth and stable operating expenses. Overall, the transcript suggests a positive short-term outlook for Amgen's stock.

[1]